Deaths Prompt Warnings On Psoriasis Drug Raptiva

Law360, New York (February 19, 2009, 12:00 AM EST) -- Genentech Inc.'s psoriasis drug Raptiva came under attack Thursday on both sides of the Atlantic after reports that three patients using the drug died of a rare brain infection. Officials in the U.S. issued a public health advisory, while their counterparts in Europe recommended a halt to Raptiva sales.

The U.S. Food and Drug Administration said in a statement that it had confirmed that four people taking Raptiva contracted progressive multifocal leukoencephalopathy, a viral infection that damages the protective sheath surrounding nerves and usually leads to...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.